Intellia Temporarily Pauses Late-Stage Gene-Editing Trials Amid Safety Concerns
Intellia Therapeutics has temporarily paused its Phase 3 clinical trials of Nex-z for transthyretin amyloidosis after a patient experienced severe liver-related side effects, with plans to investigate and consult with regulators before resuming the trials.